z-logo
open-access-imgOpen Access
Metformin and Aging: A Review
Author(s) -
Hartmut Glossmann,
O. Lutz
Publication year - 2019
Publication title -
gerontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.397
H-Index - 94
eISSN - 1423-0003
pISSN - 0304-324X
DOI - 10.1159/000502257
Subject(s) - metformin , medicine , placebo , type 2 diabetes , drug , clinical trial , adverse effect , population , diabetes mellitus , bioinformatics , intensive care medicine , gerontology , pharmacology , endocrinology , alternative medicine , biology , pathology , environmental health
Metformin is sometimes proposed to be an "anti-aging" drug, based on preclinical experiments with lower-order organisms and numerous retrospective data on beneficial health outcomes for type 2 diabetics. Large prospective, placebo-controlled trials are planned, in pilot stage or running, to find a new use (or indication) for an aging population. As one of the metformin trials has "frailty" as its endpoint, similar to a trial with a plant-derived senolytic, the latter class of novel anti-aging drugs is briefly discussed. Concerns exist not only for vitamin B12 and B6 deficiencies, but also about whether there are adverse effects of metformin on individuals who try to remain healthy by maintaining cardiovascular fitness via exercise.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom